Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696449 · ClinicalTrials.gov registry record · Phase 4
Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris
A Phase 4 study, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
NCT00696449: Completed Phase 4 study, sponsored by Wake Forest University.
NCT00696449 is a Phase 4 study that has completed, run by Wake Forest University. The registered enrollment target is 61 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00696449, a Phase 4 study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate potential differences between four treatment intervention groups in the adherence to treatment with Differin® Gel, 0.1%. Differin is approved by the Food and Drug Administration (FDA) to treat acne.
Primary Outcome
Percentage of prescribed doses taken over the 12-week study period, as measured by a Medication Event Monitoring System (MEMS) cap
Interventions
- BEHAVIORAL Standard of care
- DRUG Adapalene
- BEHAVIORAL frequent visits
- BEHAVIORAL electronic reminder
- BEHAVIORAL Parent reminder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
What the finished NCT00696449 record still lists
NCT00696449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 5 interventions - of which Standard of care is the first listed.
NCT00696449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00696449 about?
NCT00696449 is a clinical study titled "Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris". The primary objective of this study is to investigate potential differences between four treatment intervention groups in the adherence to treatment with Differin® Gel, 0.1%. Differin is approved by the Food and Drug Administration (FDA) to treat acne.
What is the current status of trial NCT00696449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2006-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00696449?
The interventions under investigation include: Standard of care (BEHAVIORAL), Adapalene (DRUG), frequent visits (BEHAVIORAL), electronic reminder (BEHAVIORAL), Parent reminder (BEHAVIORAL).
Who is sponsoring clinical trial NCT00696449?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00696449's enrollment target sits among peer trials
61 1119th of 2000 higher than 876 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia